Learn more about the latest in Alzheimer's disease research, including the Global Alzheimer's Platform Foundation’s® impact on Alzheimer's and clinical trials.
By Sydney RoellSARASOTA COUNTY, Fla. (SNN) — In honor of Sept. 21 being World Alzheimer's Day, a group of Sarasota researchers hosted a free bilingual memory screening. Intercoastal Medical Group Neurology and Research Clinic offered their free, confidential memory screening in English and Spanish on Thursday from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex in Sarasota, with free parking and refreshments. The event was for residents aged...
By Janet Lee - Washington Post Consumer Reports has no financial relationship with any advertisers on this site. Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do can help lower your risk of dementia to a greater extent than previously thought. Although...
Free, bilingual screening on World Alzheimer’s Day Intercoastal Medical Group Neurology and Research Clinic will hold a free, bilingual?memory?screening event on World Alzheimer’s Day on Sept. 21 from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex, 1845 John Rivers St., in Sarasota. The goal of the confidential? screening in English and Spanish is to increase awareness for early detection of memory loss and Alzheimer’s disease for residents...
Revolutionary Studies, Record Breaking Collaboration, and Promising News on Biomarker Studies Top the Charts at AAIC Washington D.C., Aug 31, 2023— Researchers and leaders from the Global Alzheimer’s Platform Foundation® (GAP) assembled with the world’s leading Alzheimer’s researchers, patient advocates, and clinicians at the annual Alzheimer’s Association International Conference (AAIC). From the memorable week, four key moments stood out with the potential to revolutionize current processes and practices in...
Jessica Cantu from GAP-Net site El Faro Health and Therapeutics was at the Alzheimer's Association's International Conference (AAIC) in Amsterdam and spoke about the creation of the site in Starr County, Texas. En el condado Starr, casi uno en cada cuatro adultos de 65 años de edad en adelante fueron diagnosticados con Alzheimer en el año 2021. "Me da escalofrío porque es algo que lamentablemente nos afectó a nosotros personalmente...
By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage policies for PET scans and genetic testing that help target the drug to the right...
By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that it has obtained a traditional approval – only when patients are enrolled in a registry. The...
The FDA’s approval comes following the recommendation of an FDA advisory committee, which voted unanimously for Leqembi’s full approval earlier this month WASHINGTON, DC, July 6, 2023 — Following a decision from the U.S. Food and Drug Administration (FDA) granting full traditional approval to Leqembi, a disease-modifying Alzheimer’s treatment from Eisai, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the FDA for its decision. “The FDA met its congressional mandate...
GAP Community Connector, Paula Atkinson, was a guest writer for the Orlando Times and explained why she and GAP are committed to advancing Alzheimer's clinical research in Black and Brown communities. My grandmother was treated for Alzheimer’s disease, but never diagnosed with it. Why? She was toldby her doctor that it would take too long to accurately diagnose her. This experience is repeated time after time across the Black community,...
GAP-Net Site Kerwin Medical Center was featured in Community Impact on the rate of Alzheimer's disease in Hispanic communities, and how they can help. As part of a nationwide study, Kerwin Medical Center is testing the efficacy of Aducanumab, a drug that helps a type of plaque in the brain and slows memory impairment caused by Alzheimer’s disease. To do so, the clinic is hoping to have at least 18%...
GAP-Net Site K2 Medical Research was featured in the Orlando Times speaking about the rate of Alzheimer's in the black community, and studies they have that can help. ORLANDO – For the 580,000 Floridians who are living with Alzheimer’s disease, or for the state’s 1.1 million citizens who who serve as unpaid Alzheimer’s caregivers, one thing is certain: There’s no time to lose. Alzheimer’s is a progressive disease that robs...
GAP President John Dwyer was quoted in the Financial Times talking about how the CMS decision will limit patient access to possible life saving Alzheimer's treatments. Eisai has warned that mandatory data collection by US health authorities could restrictpatient access to the Japanese drugmaker’s new Alzheimer’s treatment. The company said a decision by Centers for Medicare and Medicaid Services to restrictfinancial support for Leqembi to Alzheimer’s patients whose doctors participate...
Bio-Hermes won’t just change Alzheimer’s research and diagnostics. It has the potential to save and change lives. WASHINGTON, DC (June 14, 2023) — Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET scan, can cost thousands of dollars and are generally only available in places with large...
Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 12) - “Last week, I was proud to participate in the open public hearing session at the Food and Drug Administration (FDA)’s Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting in support of full approval of Leqembi. I wholeheartedly applaud the committee for voting unanimously to approve Leqembi for the treatment...
June 8, 2023 Mrs. Rosalynn Carter c/o The Carter Center 453 John Lewis Freedom Parkway NE Atlanta, GA 30307-1406 Dear Mrs. Carter: I read with heartfelt interest the news announcing your dementia diagnosis. Thank you for sharing this news so bravely and publicly. Receiving a dementia or Alzheimer’s diagnosis, and how that news impacts a family, is personal. Your announcement is personal, too. I come from a family in which...
GAP President John Dwyer was featured in McKnights Senior Living on the CMS decision to support only traditionally FDA-approved drugs. A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in the details.” CMS Administrator Chiquita Brooks-LaSure announced Thursday morning that the Medicare program will cover drugs that may slow the...
GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer's drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of Alzheimer’s drugs amid an intense lobbying campaign by patient advocates and drugmakers to ensure access...
News that the U.S. Centers for Medicare and Medicaid Services (CMS) will provide broader coverage for Alzheimer’s treatments lacks specifics; unclear if rural and non-hospital based physicians can participate Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 1) — “It’s too early to celebrate. The U.S. Centers for Medicare and Medicaid Services (CMS) would have us believe that this is business as...
Americans want Congress and the president to step in if CMS doesn't change its restrictive coverage policy. WASHINGTON (May 23, 2023) -- Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer's disease, according to a new poll conducted by Lake Research Partners and Public Opinion Strategies. Almost two-thirds of those polled (63%)...
GAP-Net Site The Alzheimer's Disease Research Center of Albany is looking for volunteers for their research studies. ALBANY — The Alzheimer's Disease Research Center of Albany is looking for volunteers for an Alzheimer's clinical study, putting an emphasis on the recruitment of people of color. While people from underrepresented communities — including those who are Black and Hispanic— are often not part of Alzheimer’s disease clinical trials, they are twice...
WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors are on the cusp of having another disease-modifying therapy to treat their condition. Millions of...
House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita Brooks-LaSure about the lack of coverage for groundbreaking drugs to help treat Alzheimer’s. The subcommittee...
2022 Citizen Scientist Champion Award Elevated Honoree, Bob Deady, was featured in the KU ADRC publication for his dedication to Alzheimer's research. There’s a familiar face around the University of Kansas Alzheimer’s Disease Research Center (KU ARDC). He doesn’t have an office, or a nameplate on the door or letters behind his name. But he’s doing his part for Alzheimer’s disease research and the study of other types of dementia. Meet Robert...
GAP President John Dwyer wrote an op-ed in the Dallas Examiner calling on President Biden to reverse the Centers for Medicare and Medicaid Services to cover Leqembi and future Alzheimer's drugs and treatments. The Biden administration has a big problem on its hands. It’s sending mixed signals on new Food and Drug Administration approved Alzheimer’s drugs, and patients are suffering. The Centers for Medicare and Medicaid Services is continuing an...
by Barbara Campos - Telemundo According to the conclusions of a new Alzheimer's Association report, Hispanics are almost twice as at risk as other demographic groups, and caring for patients can place a heavy burden on households. The report illustrates the need to allocate more resources and efforts to raise awareness about a degenerative disease that affects about 13% of Hispanics 65 and older. In Texas, this disease and other...
“GAP strongly encourages ICER to revamp its model to accurately reflect Leqembi’s benefits and what matters most to patients and their families” For immediate release: Washington, D.C. (March 17, 2023) — Joining other Alzheimer’s advocates, experts and researchers, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer provided written comments as part of the Institute for Clinical and Economic Review (ICER) public meeting on Alzheimer’s disease, which is evaluating the FDA-approved...
“Today, the Veterans Health Administration (VA) demonstrated enormous leadership and concern for the health of veteran’s fighting Alzheimer’s disease with its decision to cover the cost of Leqembi. Our veterans battled for us, and the VA is now giving their patients new therapies to battle Alzheimer’s.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (March 13, 2023) — “Today, the Veterans Health Administration (VA) demonstrated enormous leadership...
Jenny Knap of Bay Village joined the clinical trial for one of the treatments 6 years ago. BAY VILLAGE, Ohio — There are two newly-approved treatments to treat Alzheimer’s Disease, but getting them covered by medicare is a battle. Alzheimer’s impacts nearly 6 million Americans over the age of 65, and that number is expected to triple by 2060. It is the sixth leading cause of death in the U.S.,...
Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which have made therapies available to patients and families living with Alzheimer’s. His service at the...
“CMS’s latest decision on disease-modifying therapies for Alzheimer’s patients is effectively a coverage denial for this entire class of drugs, and patients will needlessly die as a result of it.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 23, 2023) — “Once again, the Centers for Medicare and Medicaid Services (CMS) has outrageously discriminated against 1.2 million Americans with Alzheimer’s who can benefit from a class...
The Global Alzheimer’s Platform Foundation’s® (GAP) 2022 Citizen Scientist Award recipients include the first husband-and-wife volunteer team, an Alzheimer’s advocate who champions participation in prevention studies, and a Parkinson’s disease clinical trial participant who volunteers in research studies to find hope after diagnosis WASHINGTON, DC (Feb. 22, 2023) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the recipients of the 2022 National Citizen Scientist Awards®. GAP’s Citizen Scientist...
The Global Alzheimer’s Platform Foundation® adds Lammert Albers to its team in the role of chief commercial officer; he joins GAP with leadership experience in growing clinical trial and life science technology companies WASHINGTON, DC (Feb. 21, 2023) — The Global Alzheimer’s Platform Foundation (GAP) welcomes Lammert Albers to its leadership team. Lammert has successfully grown a variety of clinical trial and CNS technology companies and will serve as GAP’s...
The Global Alzheimer’s Platform Foundation® (GAP) kicks off its annual conference in Austin, Texas, bringing together the nation’s leading Alzheimer’s researchers, scientists and advocates” WASHINGTON, DC (Feb. 20, 2023) — The Global Alzheimer’s Platform Foundation (GAP) will kick off its annual research conference Feb. 22–24 in Austin, Texas. The conference brings together leading Alzheimer’s scientists, advocates, and researchers from more than 100 independent and academic clinical research sites in North...
“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food and Drug Administration (FDA)’s decision to grant accelerated approval to lecanemab, a treatment that offers...
GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials. https://youtu.be/H8ZeuXvpKZc
Washington, DC -- December 23, 2022--Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer's disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH) are critical to addressing the increases in the number of cases of...
Washington, DC -- December 23, 2022--The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease. The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that ignores the published scientific literature and the rigorous data underpinning lecanemab’s unprecedented performance in delaying...
Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in the research, we are that much closer to helping millions of Americans slow the devastating...
GAP President John Dwyer spoke with Cathy Kelly of Pink Sheet about the Bio-Hermes study, the necessity for diversity in #Alzheimers clinical trials, and how industry-sponsored trials are out pacing government-sponsored trials. Although Alzheimer’s stakeholders are dismayed by the treatment access restrictions imposed by the Medicare national coverage determination last spring, the policy has also jumpstarted improvements in clinical trials for Alzheimer’s drugs in an important way, according to Global Alzheimer’s...
GAP President, John Dwyer, spoke to Genome Web about the closing of our Bio-Hermes study, and what the results may do for the future of Alzheimer's research. The Global Alzheimer's Platform (GAP) has completed a first-of-its-kind cross sectional study comparing the performance of Alzheimer's diagnostic assays. Topline results are expected in July of next year, with a second, longitudinal study, to be completed by the end of 2024. The researchers...
GAP-Net site, El Faro Health & Therapetuics was featured in AARP on the work they are doing to bring Alzheimer's research to the Latino and Starr County communities. On a gloomy mid-November morning in 2021, Jessica Cantú stood in the parking lot outside a health center in the rural border community of Starr County, Texas, and felt something pulling her back to her hometown.? The 45-year-old nurse practitioner was there...
The Global Alzheimer’s Platform Foundation (GAP) closed its ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, which is powered to measure more than 36 technologies’ effectiveness across three stages of Alzheimer’s disease, while drawing from all races and ethnic groups affected by the disease. WASHINGTON, DC (Nov. 15, 2022) — In 18 months, the Global Alzheimer’s Platform Foundation (GAP) recruited more than 1,000 participants to enroll in the first-ever head-to-head...
The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of enormous importance as we improve on the next generation of trials and therapies for people...
WASHINGTON, DC, Oct. 5, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and vigorously supports Congressmembers Vern Buchanan (R-FL) and Nanette Diaz Barragán (D-CA) for bringing forward a new bill to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries, including access to approved Alzheimer’s treatments. The bill — known as the “Mandating Exclusive Review of Individual Treatments (MERIT) Act” — clarifies Medicare’s national coverage determination...
WASHINGTON, DC, Sept. 28, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s disease, marking an enormous milestone for millions of people living with Alzheimer’s disease. The positive trial results, released by Eisai Tuesday night, show that the novel drug helped slow cognitive decline by 27 percent after 18 months in people who are in the early stages of...
GAP-Net Site El Faro Health and Therapeutics in Texas’ Starr County continues working to connect the area’s predominantly Hispanic community with access to Alzheimer’s research and health care. Washington, D.C. — Today, Global Alzheimer’s Platform Foundation (GAP) John Dwyer applauded the work that Dr. James Falcon and the whole El Faro Health and Therapeutics team are doing to reach the vastly underserved people in Starr County, Texas — a county...
In honor of World Alzheimer’s Day, the Global Alzheimer’s Platform Foundation continues to push for diversity in Alzheimer’s clinical trials WASHINGTON, DC, Sept. 20, 2022 — In recognition of World Alzheimer’s Day (Sept. 21), the Global Alzheimer’s Platform Foundation (GAP) is bringing its mobile research unit into Orlando-area communities. This continues GAP’s work toward increasing participation of traditionally underrepresented communities in Alzheimer’s clinical research. This summer, through a similar effort, GAP’s mobile...
GAP President John Dwyer spoke with Duane Schulthess on the Vital Health podcast about everything from the work that GAP is doing with the Davos Alzheimer’s Collaborative and the CEOI and the CMS decision several months ago. “It’s just a fact that there are a lot of us that are sick with Alzheimer’s. It is the size of the community of patients that were going to be potentially receiving the drug,...
There was justifiable ink given last month in the media to the Lesné research misconduct. But it missed the mark. The real Alzheimer’s story is the “amyloid hypothesis” related to A?*56 is a small fraction of the research being done in an industry that is funding, backed by a lot of heart, to find a treatment, prevention or cure for Alzheimer’s disease. This week, in Science, Drs. Dennis Selkoe and...
GAP-Net Site, iResearch Atlanta, hosted an event to brainstorm ways to educate community members on Alzheimer's and other dementia related diseases. Near the end of July, 10 individuals from the Global Alzheimer's Platform Foundation (GAP), MapHabit, Collaborative Real Estate, and 250 E Ponce’s very own iResearch Atlanta were exclusively invited to gather over complimentary lunch and drinks for an hour to discuss improving standards of living and understanding memory loss. ...
GAP partner, Genetech, is working with us on our Bio-Hermes study to increase diversity in Alzheimer's clinical trials. Missing a trial goal in Alzheimer’s disease is a pretty common occurrence—see crenezumab, for the latest. But Genentech’s latest reported miss was something different. The Roche unit wanted to build a clinical trial program for its lead candidate gantenerumab that reflected the people who actually get the disease. That means—according to the Alzheimer’s...
The new program will provide much-needed resources and workforce development opportunities for clinical trial sites challenged by a shortage of approved raters. WASHINGTON, DC, Aug.1 — The Global Alzheimer’s Platform Foundation® (GAP) and WCG announced a joint program today that will increase the availability of educational resources and training to support Alzheimer’s disease research. This will provide clinical research sites that serve traditionally underrepresented communities with the resources to ensure qualified individuals...
Global Alzheimer’s Platform Foundation to present information about trial diversity at the Alzheimer’s Association International Conference. WASHINGTON, DC, July 27, 2022 — As a leading organization focused on increasing participant diversity in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation® (GAP) will present data at the Alzheimer’s Association International Conference® 2022 (AAIC®) to share information about its work and research in the field. The annual conference, which brings together Alzheimer’s researchers and...
Dr. Richard Holub from GAP-Net site Neurological Associates of Albany talks about his commitment to finding a cure for Alzheimer's disease and says he won't be retiring anytime soon. Dr. Richard Holub has spent the past 40 years dedicated to Alzheimer’s research. He has treated thousands of Alzheimer’s patients and completed more than 125 clinical trials. At 74, the president of Neurological Associates of Albany is one of the longest-tenured...
Individuals who are usually at risk of developing Alzheimer's can take part in pre-screening visits at every mobile site stop. Global Alzheimer’s Platform Foundation (GAP) has introduced a new mobile health site to lower barriers to the participation of underrepresented communities in Alzheimer’s clinical trials. Around 1% of the African Americans and Hispanics with Alzheimer’s take part in trials where therapies may be available for them. This mobile research site is intended...
Global Alzheimer’s Platform Foundation’s new mobile research site is taking Alzheimer’s clinical trials on the road to traditionally underrepresented communities. WASHINGTON, DC, July 14, 2022 — Today, Global Alzheimer's Platform Foundation (GAP) announced the launch of a new mobile health site, which is hitting the road to reduce barriers to clinical trial participation. While more than six million Americans live with Alzheimer’s, African Americans and Hispanics are disproportionately affected by the disease...
GAP-Net Site Brigham and Women's Hospital Center for Alzheimer Research & Treatment (CART), was featured in their local news station about the importance of volunteer participation in clinical research. A local hospital is now part of a global effort to test a drug that may delay the devastating impact of Alzheimer's disease. The progressive neurological disorder often runs in families, so relatives of patients are eager to learn the results....
3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease Somerville, Mass., June 1st, 2022 — GNS, the leader in the use of “Virtual Patients,” Causal AI and simulation technology for biopharmaceutical drug discovery and development, and the Global Alzheimer’s Platform Foundation® (GAP) today announced a 3-year partnership. This innovative partnership will leverage the fully de-identified dataset of rich...
GAP President John Dwyer was quoted in the Wall Street Journal speaking about how the Centers for Medicare and Medicaid Services coverage decision limits Alzheimer's patients. The commercial failure of Biogen Inc.’s drug Aduhelm is putting new focus on the state of research into the causes of Alzheimer’s disease. More than six million people in the U.S. are living with the progressive type of dementia, according to the Alzheimer’s Association, an advocacy group....
GAP-Net Site, Neurological Associates of Albany, was featured in the news about a new trial they are participating in. Over the last five years, Jim Manuel says he slowly started to lose bits and pieces of his life. Pieces so small, it was easy for his wife and kids to think he was imagining it. “There are just parts that I don’t remember as clear, and I don’t trust my...
GAP-Net Site El Faro Health and Therapeutics' Dr. James Falcon was interviewed about the new research center. Starr County, a rural area along the Texas-Mexico border, has one of the highest rates of Alzheimer’s disease in the country. It’s not clear why. But physicians at a new research and treatment center in the area hope to find some answers. El Faro Health and Therapeutics opened earlier this year in Rio Grande City,...
GAP President John Dwyer was quoted in AlzForum about the Centers for Medicare and Medicaid Services (CMS) National Coverage Decision (NCD) to only cover the drug Aduhlem for those in enrolled in a qualifying clinical trial. The verdict is in—but what now? The Centers for Medicare and Medicaid Services will only cover aducanumab in the context of a clinical trial. Impassioned lobbying on both sides of the issue moved the agency to...
GAP President John Dwyer spoke about the Bio-Hermes study and why enrolling minority populations are a priority. Metro Orlando clinical trial hopes to speed up Alzheimer’s diagnoses for minorities Black people are twice as likely as white people to develop Alzheimer’s disease — Latinx people, 1.5 times as likely. But barriers including access to health care, timely diagnoses and transportation often keep clinical trials — designed to test new treatments...
GAP-Net sites Baylor College of Medicine Alzheimer's Disease and Memory Disorders Center and the Lou Ruvo Center for Brain Health at the Cleveland Clinic in Las Vegas are collaborating on a film project to bring awareness of the prevalence of Alzheimer's disease in the Latino community. Assistant director Aaron Thomas slams the clapperboard Saturday to set a crew of 20 people into motion as actors start their scene in a...
GAP-Net site El Faro Health & Therapeutics was featured in the Houston Chronicle. The disease took Noemi Fleming’s elderly mother slowly, the first hints in repeated anecdotes or phrases. Then misplaced keys and bills. Then, Fleming caught her mother walking outside in the middle of the night, looking for the newspaper. “Mama, it’s 1 o’clock in the morning,” Fleming would tell her. “The newspaper doesn’t get here until 8.” Fleming’s...
Washington, D.C. (April 7, 2022) – “Today, the Centers for Medicare and Medicaid Services (CMS) issued its final coverage ruling for an entire class of Alzheimer’s drugs. At its core, this National Coverage Decision (NCD) is not very different here from a flat-out denial of coverage. CMS continues to treat all Alzheimer's patients differently than any other class of patients. No coverage to label restricts the drugs to only a few patients and...
Modeled after DARPA, ARPA-H will incentivize innovative approaches to address some of America’s deadliest diseases Washington, D.C. (March 30, 2022) – A group of leading scientists and patient advocates today applauded the Biden Administration and Congress for making the Advanced Research Projects Agency for Health (ARPA-H) a reality. This new agency is designed to empower high-risk, high-reward strategies aimed at rapidly accelerating research and development to treat and cure disease....
GAP President John Dwyer was quoted in Pink Sheet in regard to the Centers for Medicare and Medicaid Services' proposed National Coverage Decision. The Centers for Medicare and Medicaid Services’ proposed eligibility criteria for the research sites capable of conducting clinical trials for monoclonal antibody drugs for Alzheimer’s disease could be met in just 28 states, leaving a large swath of the country without access to the drugs, according to...
GAP President John Dwyer, on behalf of the organization, joined other Alzheimer's advocates in Washington D.C. for the 'Rally for Access' on March 15, 2022. The 'Rally for Access' gathered these organizations to remind the public what is at stake if the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) is accepted. Currently, the decision would limit not only Aduhelm, the first Alzheimer's Disease drug approved in...
CMS FAILS TO FAIRLY EVALUATE ALZHEIMER’S TREATMENTS Washington, D.C. (March 23, 2022) — Adding to the growing number of advocates calling on the U.S. Centers for Medicare and Medicaid Services (CMS) to reconsider an unprecedented National Coverage Determination (NCD) that discriminates against 6 million people with Alzheimer’s disease, U.S. Senators Mark R. Warner (D-VA) and Ed Markey (D-MA), co-chairs of the Congressional Task Force on Alzheimer’s Disease, along with Senators...
A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs. UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran across the the day’s morning talk news shows. The group is the latest to push back on the Centers for Medicare and Medicaid Services’ proposed decision to only cover Biogen and Eisais’s Aduhelm and other potential...
GAP-Net Site Charter Research's Jeff Pohlig, CEO, wrote an Op-Ed about how volunteering can improve your health and your community. Unfortunately, over 90% of research studies are delayed because of slow recruitment. These delays may be affecting the treatment of your neighbor, loved one, co-worker or friend. Floridians facing Alzheimer’s need clinical trial volunteers to continue what could be life-saving research. The need to prioritize research for our community is...
Washington, D.C. (March 1, 2022) - “He did it again. From his victory speech in November 2020 and then again in his initial address to the nation in 2021, and then tonight in his most major address yet unveiling his ‘Unity Agenda,’ President Biden put Alzheimer’s disease near the top of the U.S. national public health agenda for the first time in our country’s history. The President promised to address...
Global Alzheimer’s Platform Foundation® Honorees Include the First Canadian Recipient, Advocate to Veterans, Caregiver, and First Honoree with Parkinson’s Disease Contact: Andi Zucchi – andizucchi@rational360.com, 360-927-8767 Washington, DC (February 23, 2022) – The Global Alzheimer’s Platform Foundation (GAP) is honoring four clinical trial volunteers with 2021 National Citizen Scientist Awards. This year’s recipients include the first Canadian and Parkinson’s honorees, along with an advocate for veterans, and a caregiver dedicated...
GAP President John Dwyer was featured in Pink Sheet talking about the cost of Aduhelm affecting the Centers for Medicare and Medicaid Services NCD. US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of Biogen, Inc. and Eisai Co., Ltd.’s Aduhelm was a factor in Medicare’s proposed national coverage...
MedVadis Research will join the Global Alzheimer’s Platform Foundation® Network (GAP-Net) of more than 100 global clinical trial sites Washington, D.C. (February 10, 2022) – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private research sites collaborating to accelerate the delivery of innovative therapies for neurological disorders by reducing...
Dwyer calls on Centers for Medicare & Medicaid Services to provide coverage for the entire class of mAb drugs approved by the Food & Drug Administration and future drugs yet to be approved Washington, D.C. (February 11, 2022) – The Centers for Medicare & Medicaid Services (CMS) proposed plan to limit coverage of an entire class of monoclonal antibodies that targets amyloid for the treatment of Alzheimer's is discriminatory and...
Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of development for the entire class of current and future Alzheimer’s treatments that target amyloid plaques. ...
Being Patient answers some common questions regarding the Centers for Medicare and Medicaid Services (CMS) proposal, and GAP President John Dwyer mentions how this could affect future Alzheimer's trials and treatments. The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects of their proposal toward answering the big question: Will Aduhelm be covered by Medicare? “It’s...
GAP President John Dwyer was quoted in NJ.com about the future of Alzheimer's treatments if the CMS National Coverage Decision (NCD) proposal is approved. Every day in this country, an estimated 1,000 people progress from moderate Alzheimer’s dementia to the final and most severe stage of the disease. That’s a grim statistic in its own right. But the gravity of it becomes even greater at a time when the federal...
New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on a new survey of...
Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will be from diverse populations. “Clinical trials of Alzheimer’s therapeutics commonly only include 2-3 percent of...
GAP President John Dwyer was quoted in Politico talking about the difficulty of having a diverse population pool in Alzheimer's clinical trial, and how unlike that is to achieve if the CMS proposal is approved. Drugmakers and patient advocacy groups are waging a campaign to cast Medicare officials as villains after the program limited coverage of a pricey new Alzheimer’s drug and demanded tougher criteria than the FDA to prove...
GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the announcement today by the Centers...
GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the announcement today by Biogen Inc. that it would reduce the cost of their Alzheimer’s treatment...
iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – peterbuonanno@rational360.com – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta will join its network of clinical trial sites (GAP-Net), a team of leading academic and...
Watch GAP President John Dwyer and GAP's Senior Advisor, Dr. Lynne Hughes, talk about our Ixico partnership and our Bio-Hermes study. https://youtu.be/78wmCjtbbhg
Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer's Research Contact: Peter Buonanno – peterbuonanno@rational360.com – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites the team of leading researchers collaborating on the groundbreaking Alzheimer’s Bio-Hermes Study. Bio-Hermes, which seeks...
New GAP-Net site El Faro Health and Therapeutics has opened in Rio Grande City, TX. The below article was translated from Spanish to English. The original, Spanish version is linked at the bottom. A new clinical research center to study Alzheimer’s and its impact among Hispanics, the group with the highest prevalence of this disease in the U.S., opened this past Saturday in the border city of Rio Grande, Texas....
Alzheimer’s World Directs Eyes on the Rio Grande Valley as Acclaimed Family Physician Opens New Facility in Rio Grande City with Highest Alzheimer’s Rate in the Country The Global Alzheimer’s Platform Foundation® (GAP) and Dr. Antonio Falcon celebrated the opening of El Faro Health & Therapeutics in Rio Grande City, TX on Saturday, marking a historic day for South Texas and the medical research community across the nation. This groundbreaking...
GAP-Net Site, El Faro Health and Therapeutics, was opened in Starr County, Texas led by Drs. Antonio and James Falcon. El Faro Health & Therapeutics will be the first private clinical research site in Starr County, TX. This groundbreaking initiative will bring critical Alzheimer’s-related research and care to a community that has been historically underrepresented in clinical trials. Starr County is 97 percent Hispanic and has the highest prevalence of...
GAP is proud to support the grand opening of #GAPNet El Faro Health and Therapeutics, the first private research site in Starr County, Texas. Starr County is a 97% Hispanic Community with the highest prevalence of Alzheimer's disease in America. Legendary Starr County physician and Baylor College of Medicine Trustee, Dr. Antonio ‘Tony’ Falcon is set to announce new clinical trials to research Alzheimer’s Disease in his community. Dr. Falcon...
GAP President John Dwyer commends President Joe Biden on his commitment to fight Alzheimer's, as well as calls on Congress to pass ARPA-H. Normally, presidential proclamations aren’t news. However, as the United States sinks deeper into a worsening Alzheimer’s public health crisis, President Joe Biden is making his priorities on the disease abundantly clear. Prior to the commencement of National Alzheimer’s Disease Awareness Month 2021, Biden reaffirmed his commitment to fighting against...
Microsoft and Gates Ventures founder, Bill Gates, mentions GAP's Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its estimated cost to society is more than US$1.3 trillion every year—and it could be twice...
Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures for Alzheimer’s. “Dr. Hughes will be an important contributor to GAP’s efforts to design more...
Three GAP-Net Sites, The Cognitive and Research Center of New Jersey, Princeton Medical Institute, and Advanced Memory Research Institute of New Jersey are hosting a state wide FREE memory screening for individuals 50+. If you’re worried about the threat of dementia, there’s something you can do right now to reduce your risk. Get your memory screened. That simple act of preventative care offers one of the best ways for older...
GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an Alzheimer’s patient advocate here in Tampa, I work on the front lines of the Alzheimer’s...
GAP's Bio-Hermes study was featured in BlackNews.com about our groundbreaking commitment to diversity. Washington, DC — Research sites in Florida, Illinois, Kansas, Texas, and New York are now recruiting participants for The Global Alzheimer’s Platform Foundation® (GAP)’s Bio-Hermes Study – a breakthrough Alzheimer’s clinical trial searching for cost-effective methods to assess the signs of the disease. It is the first-ever Alzheimer’s study to prioritize diversity in its recruitment goals. Black Americans 65 years...
GAP-Net site, the University of Southern California, received over 90 grants totaling $92 million in 2020. USC’s bench is deep and its scope is wide when it comes to research on Alzheimer’s disease. In Paul Thompson’s lab, researchers query a vast trove of brain images and DNA from all over the world to glean insights that would be otherwise impossible to pinpoint. Judy Pa explores how exercise and cognitive training, assisted by virtual reality, might...
GAP's Tamiko MaGee-Rodgers, Associate Director for Recruitment and Strategic Initiatives, wrote an article in the Orlando Times about the Black community getting involved in Alzheimer's disease clinical trials and the Bio-Hermes study at GAP-Net site, Charter Research. At the Global Alzheimer’s Platform Foundation (GAP), our focus is speeding the delivery of innovative therapies to people living with Alzheimer’s disease. One of our primary concerns is increasing participation from people of...
GAP-Net site, Progressive Medical Research, was featured in the Daytona Times for the Bio-Hermes study and how to get a free brain scan. The effects of Alzheimer’s disease on Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according to researchers at Florida International University and UsAgainstAlzheimer’s, by 2030 nearly 40% of all Americans with Alzheimer’s disease will be either Black or Latino. Over...
GAP President John Dwyer and GAP-Net site, Charter Research, were featured in Being Patient talking about the Bio-Hermes study, our commitment to diversity, and the tests used in the study. Scientists have made strides in improving the precision of diagnosing Alzheimer’s, but available diagnostic tools that measure Alzheimer’s biomarkers remain inaccessible for many patients. So, researchers in the Bio-Hermes study are developing more cost-effective technologies like blood and retinal tests...
GAP President John Dwyer and GAP-Net site, Axiom Clinical Research, were featured in the Florida Courier about the Bio-Hermes study and the importance of Black and African American participation in Alzheimer's trials. The effects of Alzheimer’s Disease on the Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according to researchers at Florida International University and UsAgainstAlzheimer’s, by 2030 nearly 40% of all Americans...
Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study to compare the results of blood and digital biomarker tests — including digital, cognitive, retinal,...
GAP-Net site Washington Univeristy in St. Louis' Dr. Joy Snider about the pros and cons about the approval of Aduhelm (Aducanumab). The recent FDA approval of a new Alzheimer’s drug has some researchers concerned — aside from its $56,000-a-year price tag. It’s the first Alzheimer’s drug to be approved since 2003. It’s called aducanumab and is marketed under the trade name Aduhelm. It’s had some breakthrough benefits: It’s shown to be effective...
Dr. Tamiko Magee-Rodgers joins the BNC to discuss the new Alzheimer`s drug, Aduhelm, and the role of minorities in clinical trials. Originally shown on BNC on July 9, 2021.
GAP Net site, Great Lakes Clinical Trials, spoke The Chicago Defender about GAP's Bio-Hermes study and the importance of minority communities getting involved in Alzheimer's clinical trials. Chicago’s Great Lakes Clinical Trials is now enrolling volunteers with and without memory concerns in the Global Alzheimer’s Platform Foundation’s Bio-Hermes Study. The study seeks to evaluate how blood or digital biomarker tests could best help predict the presence of amyloid plaques in...
GAP-Net site Kerwin Medical Center in Dallas and GAP President John Dwyer were featured in D Magazine talking about how the Bio-Hermes study is making it easier for diverse populations to participate in its new Alzheimer's trial. Dallas-based Kerwin Medical Center is emphasizing diversity as it enrolls patients in the Global Alzheimer’s Platform Foundation’s (GAP) Bio-Hermes study, which sets out to determine which biological marker test is most effective at...
GAP-Net site Butler Hospital Memory and Aging Program administered the first infusion of Aduhelm to a patient who wasn't involved in the clinical trial. A U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen Inc before Medicare had even said what it will pay for - and with some doctors upset by its approval last week. Mark Archambault, a 70-year-old realtor from Wakefield,...
GAP President John Dwyer spoke to THE CALL about the health disparities in Alzheimer's research and treatment between Black and African Americans compared to whites. If you have a family member or loved one going through Dementia you probably wish that you could turn back the clock about 15 years or to a time when they could remember who you are and in some cases who they are. But, hopefully...
John Dwyer, GAP President, spoke about the impact Abucanumab will have on Alzheimer's research and clinical trials going forward. The arrival of the first new Alzheimer's drug in two decades should have been a moment of celebration. But so far, the healthcare industry is feeling concerned. The US Food and Drug Administration approved the new medication, called Aduhelm, on June 7. The drug, made by the biotech company Biogen, is designed...
GAP President John Dwyer spoke to Scrip Informa Pharma Intelligence about Biogen's aducanumab, and how clinical trials are more important than ever since it's FDA approval. The requirement for Biogen, Inc. and Eisai Co., Ltd. to conduct a Phase IV clinical trialas a condition of Aduhelm’s accelerated approval raises the question of whether Alzheimer’s disease patients in the US will be willing to enroll in the trial – or in...
The talk radio station in Dallas, Texas, WBAP, recently interviewed GAP President John Dwyer. After the FDA approval of Biogen's Aducanumab, they included GAP's statement commending the FDA. WASHINGTON (AP)- Government health officials on approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration approved...
Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the announcement today by the Food and Drug Administration (FDA) that it has approved Aducanumab...
GAP Chairman, George Vradenburg, talks about a bold approach that the National Institute of Health (NIH) can take by partnering with America's best biotech and pharmaceutical research centers. The U.S. needs a bold initiative to achieve transformative progress in the fight against Alzheimer’s disease, cancer, cardiovascular disease, diabetes, and countless other diseases that cut lives short or hold them back. The best way to do this is by building on...
A student at GAP-Net site Northwestern University created Alzheimer's Brain Box, a customized box to help engage the brain and enhance mood for those living with the disease. Weinberg second-year student Victoria Da Conceicao learned at a young age what it means to fight back against adversity. As a child, she always lived near her grandmother outside of Oakland, Calif., until her family moved to follow work outside the Bay...
GAP-Net site Princeton Medical Institute's Dr. Jeffrey Apter was featured on NJ 101.5 and spoke about an Alzheimer's drug that is taking a fresh approach on treating the disease. We've heard it called the long goodbye. I can only imagine how painful it is to have your parents go through the slow decline of dementia, their memories lost to Alzheimer's to the point they don't even know who you are....
Research from GAP-Net site University of California, San Francisco finds retinal scans tie blood vessel deterioration to APOE4, the most prevalent genetic risk for Alzheimer's disease. While it has been said that the eyes are a window to the soul, a new study shows they could be a means for understanding diseases of the brain. According to new research by scientists at the UCSF Weill Institute for Neurosciences, retinal scans can...
The Bio-Hermes study will not close until 20% of its volunteers are Hispanic/Latinx, and/or African American/Black. This article is also available in Spanish. A clinical trial could lead to the creation of biomarker-based rapid Alzheimer's tests. The research called Biohermes will include older Hispanics in the study, announced the Global Alzheimer's Platform Foundation (GAP). The study will be carried out in five centers in Florida, among other points. "We may not be able to imagine it...
GAP-Net site, Inland Northwest Research, and GAP President, John Dwyer, talk about the Parkinson's disease study, PADOVA, and what it hopes to achieve. A Parkinson’s disease clinical trial is launching at 120 global sites – including Spokane – to do a broader test of an investigational drug that in an earlier phase indicated it slowed a progressive decline in motor function. Spokane’s Inland Northwest Research is seeking volunteers ages 50...
GAP-Net site, Clarity Clinical Research, was featured on CNYCentral about their participation in the Bio-Hermes study. Clarity Clinical Research, a Syracuse research group, is looking for volunteers in an Alzheimer's risk study. The study includes three visits with no-cost amyloid PET scans that are designed to predict or possibly diagnose Alzheimer's disease. Brain amyloid plaques are sticky “clumps” of protein that build up around brain nerve cells and disrupt healthy...
GAP President John Dwyer was on RochesterFirst.com to talk about the ground breaking Bio-Hermes study and what it means for the future of Alzheimer's detection. Click here to watch the full interview. In the next few years – we could expect Alzheimer’s detection to be as easy and accessible as ordering up a blood test, that’s according to John Dwyer, CEO of the Global Alzheimer’s Platform Foundation. In order to reach...
GAP President John Dwyer spoke to Alzforum about the Bio-Hermes study. With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick, simple ways to screen patients and determine if they have amyloid plaque in their brains. The current gold-standard diagnostics used in research—amyloid PET scans and cerebrospinal fluid biomarkers—are expensive, invasive, or not readily available to many patients. With that in...
GAP-Net Site Clarity Clinical Research talks about their participation in GAP's Bio-Hermes Study. Syracuse, N.Y. — A Syracuse research clinic is seeking volunteers for a brain scan that may help predict or diagnose Alzheimer’s disease before symptoms appear. Clarity Clinical Research is one of 10 clinics nationwide offering no cost Amyloid PET scans as part of a new research study. Brain amyloid plaques are sticky clumps of protein that build...
GAP President John Dwyer was quoted in a New York Times article along side three Alzheimer's volunteer participants in the donanemab clinical trial by Lilly, a GAP partner. Despite the urgent need for treatments to slow or stop Alzheimer’s disease, finding patients for clinical trials has been difficult and frustrating. Patients are often older. Their doctors may not be part of a research network. And many with dementia never get...
Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who are contributing to GAP’s Bio-Hermes Study. Bio-Hermes is the first-ever platform study to compare results...
GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson's disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) accelerate recruitment processes with GAP Network (GAP-Net) sites across North America, including Inland Northwest Research....
GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage Alzheimer’s Disease. Aducanumab offers disease-modifying benefit significantly exceeding current therapies. It will provide long-overdue and...
GAP-Net site USF Health has received a grant from the NIH to study a computerized brain training exercise, and if it can reduce the disk of Alzheimer's disease and other dementias. The National Institutes of Health (NIH) has awarded the University of South Florida (USF) total expected funds of $44.4 million over the next five years to study whether computerized brain training exercises can reduce the risk of mild cognitive...
GAP-Net Site KU ADC has received over $1.3 million to research how exercise supports the brain as humans age. TOPEKA, Kan. (WIBW) - The University of Kansas Alzheimer’s Disease Center has received over $1 million to research how exercise could prevent Alzheimer’s. Senator Roger Marshall (R-Kan.) says the University of Kansas Alzheimer’s Disease Center has gotten over $1 million from the U.S. Department of Health and Human Services to research...
GAP-Net site Kansas University ADC was granted $4.3 million from the NIH to elevate dementia care in Kansas communities. Dementia researchers are convinced the path to beating back the life-robbing disease goes directly through clinical trials fueled by research volunteers willing to join the battle. That's why the experts at the University of Kansas Alzheimer's Disease Center put so much energy into recruiting people to participate in its abundant number of active...
GAP President John Dwyer speaks about GAP's participation in the original Trailblazer trial, and our goals for TRAILBLAZER-ALZ 2. It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite some positive signals from four such antibodies, the data have been messy and hard to interpret. At the 15th...
GAP-Net site Knight ADRC at Washington University in St. Louis received two grants to determine whether driving changes can identify people with mild and very mild cognitive impairment, and maybe even identify people in the earliest stage of Alzheimer’s disease. Every day in the U.S. in 2018, motor vehicle crashes killed more than 20 people over age 65 and injured almost 700. Older adults are the most responsible drivers of...
TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research centers available to enroll participants in TRAILBLAZER-ALZ 2. This study will determine whether the initial...
GAP-Net Site, The Cognitive and Research Center of New Jersey, talks about their participation in the GREEN MEMORY trial. The Alzheimer’s Drug, Oligomannate, approved in China and derived from seaweed, is now being studied in the U.S. in a Phase 3, multi-center clinical trial that is actively recruiting participants. Oligomannate, a drug made from seaweed and used for the treatment of Alzheimer’s Disease, has been available to patients in China since 2019....
GAP President John Dwyer spoke about the Green Valley clinical trial's success in China, which is now being tested in North America. A new drug extracted from seaweed and inspired by traditional Chinese medicine has come to the United States, where researchers hope it will provide the breakthrough in Alzheimer’s treatment that has eluded us for nearly two decades. The drug — oligomannate — has an imposing name but a...
GAP Chairman, George Vradenburg, and The Women's Alzheimer's Movement founder, Maria Shriver, co-wrote a piece on what the Biden Administration needs to do to start fulfilling their promises made to Alzheimer's patients and researchers. No president has entered the White House with as clear a focus on Alzheimer’s disease as Joe Biden. The commitment and attention on Alzheimer’s at the highest levels of our elected leadership is long overdue. His pledge during...
GAP-Net site Clarity Clinical Research issued the first treatment to volunteer Mark Cornue in the GREEN MEMORY study. Last week, Clarity Clinical Research administered the first research treatment in the world for the Green Memory study to Mark Cornue, a local Jordan resident and Alzheimer’s patient. The Green Memory study is a noninvasive Alzheimer’s disease clinical trial researching whether rebalancing certain bacteria in the gut improves brain function. “I lost my father...
GAP-Net site Kerwin Medical Center's Citizen Scientist, Dominic Morello, a caregiver for his father with Alzheimer's, wrote an Op-Ed on how this generations Alzheimer's patients can make the disease a thing of the past. There are more than 100 potential Alzheimer’s treatments in the pipeline, but the majority of clinical trials for potential Alzheimer’s therapies are delayed due to enrollment shortages. Dominic Morello, a Global Alzheimer’s Platform Foundation 2020 Citizen Scientist award nominee, shares his...
Some of our 2020 Citizen Scientist National Honorees were congratulated by their local officials on their social media pages. We have compiled the links here. Dr. Collins Lewis, Cornerstone Award National Honoree Missouri Senator Roy Blunt https://twitter.com/GAP_Foundation/status/1359889078657949701?s=20 Missouri Senator Karla May https://twitter.com/GAP_Foundation/status/1360257568501862400?s=20 Congress Women Amy Wagner https://twitter.com/RepAnnWagner/status/1359982611133784065?s=20 Brentwood, Missouri Mayor David Dimmitt https://twitter.com/DimmittDavid/status/1359875664317399049?s=20 Representative Matt Willhite, Collaborator Award National Honoree Representative Lois Frankel https://twitter.com/RepLoisFrankel/status/1359959798435971078?s=20
Dr. Collins Lewis, 2020 Citizen Scientist Cornerstone Award National Honoree, from GAP-Net site Knight Alzheimer Clinical Trial Unit at Washington University in St. Louis was congratulated for his participation in Alzheimer's disease clinical trials by Missouri senator Roy Blunt. Dear Dr. Lewis, It is my pleasure to join your family, friends, and colleagues in congratulating you for receiving the National Citizen Scientist Cornerstone Award. Your extraordinary efforts to support local...
GAP Chairman George Vradenburg and Dr. Jeffrey Cummings co-wrote an opinion piece about why the FDA and Alzheimer's disease scientists, regulators, and business leaders must work together to achieve a safe, effective drug for Alzheimer's treatment. As the Food and Drug Administration moves closer to a decision about whether to approve a promising new Alzheimer’s treatment, the collaboration between scientists, regulators, and business leaders that produced this encouraging drug has come...
GAP-Net site JEM Research Institute talks about what COVID-19 trials and vaccines tell us about Alzheimer's disease trials, and the need for volunteers. The White House hopes to vaccinate 100 million people in the first 100 days of the new administration. That would be a historic accomplishment from the virus to the vaccine in less than a year. In the second part of our special report, the CBS 12 News I-Team...
GAP-Net site, the University of California Irvine's UCIMind is quoted about how music may play a role in preserving memory and delaying Alzheimer's disease. IRVINE (CBSLA) — On Monday, it was revealed that legendary singer Tony Bennett has been battling Alzheimer’s disease for more than four years. On Monday, it was revealed that singer Tony Bennett, seen here in April 2018, has been battling Alzheimer’s disease for more than four years. (Photo by...
GAP-Net site Cleveland Clinic was awarded a grant by the NIH to evaluate if high-intensity exercise can prevent development of Alzheimer’s disease. The National Institutes of Health has awarded Cleveland Clinic a $6.7 million grant to evaluate if high-intensity exercise can prevent development of Alzheimer’s disease. The five-year study will assess the effect of home-based indoor cycling in slowing disease progression in healthy older people at high genetic risk for developing the...
Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s patients, their families, and researchers are heartened and hopeful to see strong evidence that the...
Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI): Today’s announcement by Biogen and Apple marks a significant step on the path to early diagnosis of mild cognitive impairment (MCI), the precursor to Alzheimer’s. By applying world-class neuroscience expertise...
A clinical trial participant from #GAPNet site, JEM Research, talks with her husband about their experience in the Aducanumab trial, which is pending approval by the US Food and Drug Administration by March 2021. There are currently more than five million Americans living with Alzheimer's disease… and despite ongoing research, there has been no new approved drug for Alzheimer's since 2003. Now, a new drug that is showing mixed results...
GAP 2020 Citizen Scientist Collaborator Award National Honoree, Rep. Matt Willhite was named to the Florida House Alzheimer’s Disease Advisory Committee. This week, state House Speaker Chris Sprowls, R-Palm Harbor, reached across the aisle to name state Rep. Matt Willhite, D-Wellington, to the Alzheimer’s Disease Advisory Committee. The Alzheimer’s Disease Advisory Committee has 15 members and meets every quarter to help the state Department of Elder Affairs (DOEA) “regarding legislative, programmatic and administrative matters...
GAP CSO, Dr. Richard Mohs, testified in front of US Senators about Alzheimer's disease. He was quoted by RFD TV about how it affects rural America. While many of us are focused on the pandemic, chances are you know someone who is battling Alzheimer's disease. Healthcare experts call it an epidemic in rural America. Lawmakers want to know if lessons learned from COVID-19, can offer strategies to fight dementia. Alzheimer's...
Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, Subcommittee on Health Care about the state of Alzheimer’s Disease (AD) research, the need for...
GAP-Net site Stanford Neurology and Neurosurgery Clinical Trials at Stanford University talked about how researchers have gotten creative when it comes to continuing clinical trials during the COVID-19 Pandemic. At the beginning of the coronavirus pandemic, clinical trials came to a screeching halt. But as researchers and doctors have gained a better understanding of SARS-CoV-2, the virus that causes COVID-19, they've found ways to resume essential clinical trials that help...
Citizen Scientist Mike O'Brien from GAP-Net site JEM Research is participating in the Biogen clinical trial for Aducanumab, which is under consideration by the US Food and Drug Administration (FDA). Sue and Mike O'Brien moved to South Florida about six years ago. One of her favorite sayings back then was 'Really'? One night she realized she said too many 'reallys' in one day. "I asked him to do something, he...
Dr. Chuang-Kuo Wu, the new Director of GAP-Net site Alzheimer’s Disease and Memory Disorders Center at Rhode Island Hospital spoke with NBC10 about the latest developments in #Alzheimers research. Watch the full interview or read the highlights below. As Alzheimer's Awareness Month comes to a close, there is a reason for hope. There have been no new FDA approved drugs to treat Alzheimer's disease in the last two decades, but...
GAP-Net site Brigham and Women's Hospital spoke to BioSpace about the emerging data in Alzheimer's research and what that means for treatments. There may be nothing quite as gut-wrenching as sitting at the bedside of a loved one, watching helplessly as their life comes to an end. Perhaps the only thing more painful is when that loved one no longer recognizes you, slipping away not knowing who it was holding...
Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench. “Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly available data collected and analyzed on the AD Workbench platform will spur collaboration and expedite...
2020 Citizen Scientist Cornerstone Award National Honoree Dr. Collins Lewis was featured for his efforts to encourage people from different racial backgrounds to participate in Alzheimer's clinical trials. It’s not hard to understand why most medical research projects would benefit from a robust, varied set of study subjects. But sometimes, the pool of participants doesn’t accurately reflect the ethnic diversity of society, says psychiatrist Dr. Collins Lewis, a professor emeritus...
GAP-Net site Lou Ruvo Center in Las Vegas was featured for National Alzheimer's Disease Awareness Month. The full interview can be found using the link at the bottom of this page. In Las Vegas, there are nearly 50,000 people battling the disease and more than 5 million around the country. The challenges of a loved one suffering from a brain disease can impact you in different ways, The Lou Ruvo...
GAP was mentioned for our partnering with the European Prevention of Alzheimer's Dementia (EPAD) to bring diversity and more volunteers to clinical trials. Recruiting asymptomatic participants for secondary prevention trials such as AHEAD 3-45 is no small feat. How do you find people who are well on the road to Alzheimer’s disease but feel fine, thank you very much? Scientists cut their teeth on this quest with the Anti-Amyloid Treatment...
2020 Citizen Scientist Awards National Cornerstone Honoree Dr. Collins Lewis was featured in the St. Louis Times for his participation in Alzheimer's clinical trials. NATIONAL CITIZEN SCIENTIST CORNERSTONE AWARD The Global Alzheimer’s Platform Foundation® (GAP) has recognized St. Louis psychiatrist Dr. Collins Lewis as the honoree of the National Citizen Scientist Cornerstone Award®. The Charles F. and Joanne Knight Alzheimer’s Disease Research Center at Washington University (Knight ADRC), where Dr....
GAP-Net site Clarity Clinical Research enrolls the first participant in the Green Memory Study out of 200 participating clinics. As the two walk through the heart of Jordan, his head is filled with facts and memories. “There’s some nice little antiques in there,” Mark says, passing a store. “The kids would go swimming down there,” he adds, crossing over a creek. It seemed like every building we passed, Mark knew...
GAP President John Dwyer says aducanumab offers disease-modifying benefit significantly exceeding current therapies Contact: Pamela Larkin, 408-466-5952, pamelalarkin@rational360.com Washington, DC (November 6, 2020) – Today, the President of the Global Alzheimer’s Platform Foundation® (GAP), John Dwyer, testified before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee regarding Biogen’s breakthrough Alzheimer’s drug aducanumab. Given that clinical trial data of aducanumab showed significant effectiveness in treating Mild Cognitive Impairment and that this...
2020 Citizen Scientist National Collaborator Awardee, Rep. Matt Willhite from GAP-Net site JEM Research Institute, was featured for his involvement and support for his mother's Alzheimer's clinical trial. The Global Alzheimer’s Platform Foundation (GAP) has recognized State Rep. Matt Willhite (D-District 86) as the honoree of the National Citizen Scientist Collaborator Award. JEM Research Institute, part of the Headlands Research organization, where Willhite is a study partner for his mother,...
GAP-Net site ADMDC at Lifespan Rhode Island Hospital's citizen scientist nominees were featured about their involvement, as well as GAP President John Dwyer. The Alzheimer’s Disease and Memory Disorders Center (ADMDC) at Lifespan Rhode Island Hospital, a national leader in Alzheimer’s disease care and research, has nominated five clinical trial volunteers for the Global Alzheimer’s Platform Foundation’s (GAP) 2020 National Citizen Scientists Awards®. These nominations are an opportunity to recognize and celebrate remarkable volunteers for their dedication, passion, and...
2020 Citizen Scientist Catalyst Award Honoree, Dennis Chan, was interviewed on his involvement with Alzheimer's clinical trials and why it's important to him. When Dennis Chan’s wife started to struggle with memory loss, the family began a quest to learn more. They began seeking more information about Alzheimer’s disease -- a progressive disease that leads to the wasting away and death of brain cells. With the urging of his children,...
Contact: Pamela Larkin, 408-466-5952, pamelalarkin@rational360.com Washington, DC (October 29, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding C2N Diagnostics’ release of the PrecivityADTM blood test. “Congratulations to the C2N Diagnostics team for successfully developing the first blood test of its kind for Alzheimer’s disease. It will transform how doctors treat patients and greatly accelerate the discovery of therapies and cures. Having an...
The 2020 Citizen Scientist Cornerstone Awardee, Dr. Collins Lewis, was featured for his work in increasing diversity in Alzheimer's clinical trials. A Brentwood man has received a national award honoring Alzheimer’s disease research participants for his work to create more diversity in studies to find treatments and cures. Dr. Collins Lewis, 75, a psychiatrist for the VA St. Louis Health Care System and professor emeritus at Washington University, was chosen...
The Global Alzheimer’s Platform Foundation® Recognizes Rep. Matt Willhite (D-86) with the 2020 National Citizen Scientist Collaborator Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Contact: Belinda Russel – brussell@jemri.net, 561-968-2933 West Palm Beach, FL (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized State Representative Matt Willhite (D-86) as the honoree of the National Citizen Scientist Collaborator Award®. JEM Research Institute (JEM), part of the Headlands Research ...
The Global Alzheimer’s Platform Foundation® Recognizes Deborah Whelan with the 2020 National Citizen Scientist Champion Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Contact: Robert Briggs – robert.briggs@rsfh.com, 267-879-1762 Charleston, SC (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized Deborah Whelan, a retiree living with Alzheimer’s disease, as the recipient of the National Citizen Scientist Champion Award®. The Roper St. Francis Research and Innovation Center, where Whelan has volunteered in four Alzheimer’s clinical trials,...
The Global Alzheimer’s Platform Foundation® Has Recognized Dennis Chan for the 2020 National Citizen Scientist Catalyst Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Boston, MA (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized Westford retiree Dennis Chan as the honoree of the National Citizen Scientist Catalyst Award®. The Center for Alzheimer Research and Treatment (CART) at Brigham & Women’s Hospital, where Chan volunteers in the A4...
The Global Alzheimer’s Platform Foundation® Has Recognized Dr. Collins Lewis for the 2020 National Citizen Scientist Cornerstone Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 St. Louis, MO (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized St. Louis psychiatrist Dr. Collins Lewis as the honoree of the National Citizen Scientist Cornerstone Award®. The Charles F. and Joanne Knight Alzheimer’s Disease Research Center at Washington University (Knight ADRC),...
Global Alzheimer’s Platform Foundation® National Honorees Include an Advocate with Alzheimer’s Disease, a Doctor with a Family History of Alzheimer’s, a Caregiver and Legislator, and a Retiree in a Clinical Trial Washington, DC (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) is honoring four Alzheimer’s disease clinical trial volunteers with the 2020 National Citizen Scientist Awards®. This year’s honorees include a psychiatrist with a family history of Alzheimer’s...
Randall Bateman, a researcher from GAP-Net site Washington University in St. Louis, is being elected to the National Academy of Medicine for his work in Alzheimers research. Deanna M. Barch, an expert in cognitive and language deficits in psychological disorders, and Randall J. Bateman, MD, a leading Alzheimer’s disease researcher, have been elected to the National Academy of Medicine, a part of the National Academy of Sciences. Membership in the organization is extended...
GAP-Net sites UC San Francisco and UC Irvine are collaborating with the National Asian Pacific Center on Aging (NAPCA) to develop a registry for Asian Americans and Pacific Islanders. How can Asian Americans and Pacific Islanders benefit from scientific research? Researchers at the University of California need you and your community to support the efforts. UC San Francisco, UC Davis, UC Irvine, National Asian Pacific Center on Aging (NAPCA), International...
GAP-Net site Rhode Island Hospital's 5 Citizen Scientist Award® nominees were featured on why they became involved in Alzheimer's research. PROVIDENCE – Five people who have racked up years of participation in clinical trials for Alzheimer’s disease treatments at Rhode Island Hospital are in the running for national recognition. The hospital’s Alzheimer’s Disease and Memory Disorders Center nominated the group for the Global Alzheimer’s Platform Foundation’s 2020 National Citizen Scientists...
GAP-Net site, Okanagan Clinical Trials, sent a letter to the editor of a local publication on World Alzheimer's Day on reasons why you should get involved in a clinical trial. Dear Editor: World Alzheimer’s Day was this week, and Okanagan Clinical Trials wants you to have your memory tested in celebration. While I know it may seem like a daunting prospect, I am here to tell you that just like...
GAP-Net site Banner Alzheimer's Institute in Tucson was gifted $10 million for dementia care and caregiver support. Acharitable $10 million gift has been committed to Banner Alzheimer’s Institute for innovative dementia care and caregiver support for patients and families living with Alzheimer’s disease and other memory disorders. There are three institutes in Arizona, including the Toole Family Memory Center in Tucson. The other two are the Stead Family Memory Center...
A 2020 Citizen Scientist Award Nominee wrote an opinion piece on her reason for getting involved in Alzheimer's clinical trials and how her trial was her saving grace during the COVID-19 pandemic. Ann Bellotti is a former clinical social worker and an Alzheimer’s clinical trial volunteer at the Alzheimer’s Disease and Memory Disorders Center (ADMDC) at Rhode Island Hospital. This year, ADMDC nominated Ann for the Global Alzheimer’s Platform Foundation’s...
Citizen Scientist Nominee, Florida state Representative Matthew Willhite, writes about his mother's experience with Alzheimer's disease and GAP-Net site, JEM Research Institute. Before she was diagnosed with Alzheimer’s disease, my mom was a nurse for 30 years. Her compassion for others and her tireless strength inspired me to become a Navy corpsman, a firefighter, a state representative and her caregiver — or as we like to call it, her care friend....
GAP-Net site Cleveland Clinic is hosting the Cleveland Walk to End Alzheimer's on October 4, 2020. Guest columnist Caroline James is the Business Development Specialist at Independence Village & StoryPoint Avon Lake and Retention Chair for the Cleveland Walk to End Alzheimer’s. I’ve worked in senior care for seven years, often helping those with dementia or Alzheimer’s disease live their best life possible. I’ve advocated for quality patient care. I’ve met with...
GAP President John Dwyer was featured in ACRP about what clinical trials need to be doing to increase awareness and hasten treatments. The clinical trial industry continues to grapple with finding new and more effective ways to expand its efforts to combat Alzheimer’s. The obstacles are real. Alzheimer’s trials cost more per patient than trials in many other therapeutic areas. Screening accounts for 50–70% of the total per-patient expense, as...
Citizen Scientist nominee, Florida State Representative Matt Willhite, from GAP-Net site JEM Research Institute, speaks about his mother's Alzheimer's diagnosis and involvement in Biogen's clinical trial. Surprise and skepticism greeted the Biogen company’s announcement that clinical trials of an antibody called aducanumab were resuming this year. Not only that, Biogen asked the federal Food and Drug Administration to give expedited approval to the antibody treatment that targets amyloid plaque in...
GAP President, John Dwyer, was featured in a Wall Street Journal article on the importance of Black, African-American, Hispanic and Latinx communities being aware of and enrolling in Alzheimer's clinical trials, and what GAP is doing to help. Brian Van Buren applied to five Alzheimer’s disease clinical trials after being diagnosed with mild cognitive impairment and losing his mother and aunt to the illness. He wanted to participate despite a...
GAP's statement: Study cites limited awareness among patients and physicians, anxiety, and lack of quick diagnostics Washington, DC (August 20, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding a University of Southern California Louis D. Schaeffer Center for Health Policy & Economics white paper, “Key Barriers to Clinical Trials for Alzheimer’s Disease,” which accurately diagnoses why Alzheimer’s research is struggling to recruit...
GAP-Net site, Syrentis Clinical Research, and GAP President, John Dwyer, were interviewed about the difficulties of recruiting Alzheimer's clinical trial volunteers in the time of COVID-19, and why their involvement is important. Alzheimer’s disease researchers fear that fewer volunteers and delayed studies due to COVID-19 may hinder the discovery of important treatments for the illness. Since the pandemic began, clinical trial sites across the country have had difficulty attracting volunteers...
GAP-Net site, Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, was included in the KNPR Top Doctors in Southern Nevada of 2020. How the Top Doctors are selected Castle Connolly Top Doctors is a healthcare research company and the official source for Top Doctors for the past 25 years. Castle Connolly's established nomination survey, research, screening, and selection process, under the direction of an MD, involves many hundreds...
GAP-Net Site Lou Ruvo Center for Brain Health at Cleveland Clinic Las Vegas was quoted about how microbiomes in the gut can affect the brain and lead to Alzheimer's disease. SHANGHAI, July 29, 2020 /PRNewswire/ -- Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research...
Washington D.C. (July 30, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding recent groundbreaking advances in Alzheimer’s blood test research: “I want to congratulate and thank Dr. Barthélemy, Dr. Horie, Dr. Sato, Dr. Bateman, Dr. Palmqvist, Dr. Janelidze, and Dr. Quiroz on their published research on two profound breakthroughs regarding Alzheimer’s blood biomarkers this week. These seminal research papers showed that select...
GAP-Net site Washington University in St. Louis helped develop one of the tests that has diagnosed the disease as accurately as methods that are far more expensive or invasive. Banner Alzheimer's Institute was also mentioned as a senior author. A newly developed blood test for Alzheimer’s has diagnosed the disease as accurately as methods that are far more expensive or invasive, scientists reported on Tuesday, a significant step toward a...
GAP-Net site Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas was featured on FOX5 about Alzheimer's clinical trial setbacks due to COVID-19, and how important minority communities are to research. Click here to watch the full interview. LAS VEGAS (FOX5) -- Dr. Aaron Ritter with the Cleveland Clinic Lou Ruvo Center for Brain Health was very candid in how the pandemic has set them back in a...
Dr. Jeffrey Cummings from GAP-Net site, Lou Ruovo Center for Brain Health at Cleveland Clinic in Las Vegas was interviewed by NeurologyLive about developments in Alzheimer's disease research that are worth holding out hope for. A systematic review of Alzheimer disease (AD) treatments currently in development demonstrate the progressive emphasis on nonamyloid targets, including candidate treatments addressing for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. Led...
Below is a press release from GAP-Net site, Okanagan Clinical Trials, regarding a high profile member of the community completeing a memory assessment. Kelowna (July 21, 2020) – Maxine Dehart, local city councillor, hotelier and journalist, decided to book a memory assessment for herself after featuring Okanagan Clinical Trials as part of her Straight from DeHart column in May. Okanagan Clinical Trials, a medical research centre located in Kelowna, provides free, comprehensive assessments to...
GAP-Net sites Butler Hospitals Memory and Aging Program and Rhode Island Hospitals Alzheimer's Disease and Memory Disorders Center were featured on 10WJAR in Providence, RI about an Alzheimer's clinical trial that looks to prevent the disease before symptoms occur. A new clinical trial is aimed at preventing Alzheimer’s years before symptoms arise. There will be 100 sites worldwide; two of them are in Rhode Island, recruiting men and women 55-80...
GAP-Net site Brigham and Women's Center for Alzheimers Research and Treatment received a $25 million donation. Brigham and Women's Hospital has received a $25 million gift to establish and support a new Alzheimer's prevention program, the Boston-based organization said July 13. The gift, from Andrew and Kate Davis and the Shelby Cullom Davis Charitable Fund, will be used to advance research working to predict and ultimately prevent Alzheimer's disease. "Our talented...
GAP-Net site Brigham and Women's CART was featured with two of their Citizen Scientists in the Boston Business Journal about COVID-related delays and the dedication of AD volunteers. Joining a clinical trial may not be the first idea that pops into your head when wondering how to make new friends after moving to a new area. But for Alice Bailey, it was the "most incredible gift." Bailey, 77, and her...
GAP-Net site, UCI Mind at the University of California Irvine, was awarded an Alzheimer's research grant by the National Institute of Health The National Institutes of Health has awarded $14.4 million to the UCI MIND institute at UC Irvine to continue its crucial work in the study of Alzheimer’s disease, for which there remains no cure or prevention. UCI MIND, formally known as the Institute for Memory Impairments and Neurological...
GAP President John Dwyer wrote a piece in The Hill urging Congress to ensure research centers involved in Alzheimer's clinical trials will have access to COVID-19 relief funds. COVID-19 has had a devastating impact on clinical trials and the medical research infrastructure that scientists depend upon to develop new drugs for Alzheimer’s and all the diseases we fear most. Without action, this pandemic could delay cure or treatments for Alzheimer’s for years to come. Congress must ensure that...
Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer's research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular accomplishment of Biogen and the broader research community. Most importantly, it is a testament to...
GAP President, John Dwyer, and GAP-Net site Great Lakes Clinical Trial spoke on the hit Alzheimer's clinical trials have taken since COVID-19, and the losses that will come of it. After a frustrating 2019, Alzheimer’s researchers had reason to look forward to 2020 as a year of promise. Then the pandemic struck. “Last year, seven [Alzheimer’s clinical] trials were stopped. The portfolio was more than halved,” said John R. Dwyer,...
Alice Bailey, a GAP Citizen Scientist Award nominee, wrote an Op-Ed piece in the Cambridge Chronicle about her experience as an Alzheimer's patient and clinical trial volunteer. For many seniors, Alzheimer’s disease is surrounded by fear. Fear of the diagnosis can be so strong that some don’t want to learn about or talk about the disease. And it is scary -- before COVID-19, Alzheimer’s was in the top-10 causes of...
GAP President John Dwyer and GAP-Net Site Roper St. Francis Healthcare Research and Innovation Center in Charleston, South Carolina were featured on LIVE 5 WCSC News about the need for Alzheimer's clinical trials to begin again. CHARLESTON, S.C. (WCSC) - Medical experts are worried that the COVID-19 pandemic has put delays on the search for a cure for Alzheimer's. John Dwyer is the president of the Global Alzheimer’s Platform Foundation,...
GAP President John Dwyer was quoted in AlzForum about the challenges and changes in Alzheimer's clinical trials due to COVID-19. As Alzheimer’s research comes to, scientists are taking stock of the damage. In the academic world, the main cost was time (see Part 1 of this story). For most clinical studies, the damage was more tangible, with at least a brief interruption in dosing, and a complete halt of recruitment. Larger trials...
GAP-Net Site, Brigham and Women's Center for Alzheimer's Research and Treatment, and GAP President, John Dwyer, were featured on Boston 25 News talking about how Alzheimer's Clinical Trial volunteers and researchers are getting back on track after COVID-19 setbacks. The pandemic has put a pause on critical medical research. At Brigham and Women's Hospital, some health care workers involved with a clinical trial for Alzheimer's were called to help care...
GAP-Net site Great Lakes Clinical Trials in Chicago was featured in the Chicago Sun Times, where they discussed the difficulties of attracting Alzheimer's disease trial participants during COVID-19. Jim Butler is receiving his monthly 45-minute infusion of drugs. What kind of drugs? He doesn’t know. Nor do the nurses administering them. Could be an experimental medicine that will help his brain fight Alzheimer’s disease. Or could be a placebo that...
In February, Stomping Ground Comedy Theater lead a workshop for caregivers about how to best interact with loved ones living with Alzheimer's disease or dementia. They also attended our 2020 GAP-Net Site Optimization Conference at the end of February. Above Photo: Lindsey Goldsapp of Stomping Ground Comedy Theater leads a workshop for caregivers at the Preston of the Park Cities. (Jennifer Trotter / Global Alzheimer's Platform Foundation) About 20 strangers...
June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country today. As we work with our GAP-Net sites, sponsors, funders and friends, we strive to...
This editorial was run in the Kelowna Daily Courier on May 20, 2020, on Clinical Trials Day during Clinical Trial Awareness Week. Dr. Kim Christie is the President of GAP-Net Site Okanagan Clinical Trials in Kelowna, British Columbia in Canada. Today is Clinical Trials Day, an observance commemorating the first controlled clinical trial conducted by James Lind on May 20, 1747. Much has changed since Lind studied scurvy in sailors,...
GAP-Net Site, the University of Kansas Alzheimer's Disease Center's (KU ADC) Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. The University of Kansas Alzheimer's Disease Center's Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. Presented by the KU Medical Center Office of Diversity, Equity and Inclusion, the annual honor highlights the significant...
Dorene M. Rentz, PsyD, from GAP-Net site Brigham and Women's Center for Alzheimer's Research and Treatment, and Professor of Neurology at Harvard Medical School co-authored Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1. You can find the study posted in The Journal of Alzheimer's Disease on May 19, 2020. INDIANAPOLIS, May 19, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced baseline results...
Global Alzheimer's Platform Foundation president, John Dwyer, was quoted on how GAP is supporting GAP-Net sites during the COVID-19 pandemic, emphasizing the importance of safety and remote clinical trial testing. The coronavirus pandemic is upending not only life as we knew it, but Alzheimer’s clinical studies as well. In the United States, Europe, and Australia, most sites have put observational cohort studies on hold, and many have stopped dosing and...
A participant might commit months or years to a drug trial, only to see it vanish overnight. John Poritsky was enrolled in a clinical trial for a drug to treat early Alzheimer’s disease. But the trial was canceled abruptly and publicly, before researchers gave him notice.Credit...Michelle Gustafson for The New York Times On March 21, 2019, the staff at the Penn Memory Center in Philadelphia was scrambling to learn more...
A site in the Global Alzheimer's Platform Foundation's network, ClinCloud Clinical Research, was featured on FOX35 Orlando on March 4, 2020 at 6pm. Click here to watch the segment. MAITLAND, Fla. - Researchers have been spending years trying to cure Alzheimer's Disease. We've seen several medical breakthroughs in Central Florida, but they are still running into problems. They have answers and tests, but no one to try them. There is so much fear...
This past week, the Global Alzheimer’s Platform Foundation, which works with a national network of clinical research centers, held its annual Site Optimization Conference in Orlando. The conference brings together the leaders of more than 80 clinical trial sites throughout the U.S. and Canada who work day in and day out to identify a cure for Alzheimer’s disease. More than 580,000 Floridians have Alzheimer’s disease, a progressive brain condition for...
A Spanish translation of the article below can be found on Orlando Sentenial posted on February 27, 2020 by Ginayra Alvarado Villegas. According to statistics from the Alzheimer’s Association in the United States, every 65 seconds a person develops Alzheimer’s disease, a disease that has doctors and researchers conducting studies to develop a drug or treatments that combat this type of dementia that develops mainly in older people. The disease...
CHICAGO, Feb. 27, 2020 /PRNewswire/ -- The number of commercially insured Americans age 30 to 64 diagnosed with early-onset dementia or Alzheimer's disease increased by 200% from 2013 to 2017. The average age of a person living with either form of dementia is 49. The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, "Early-Onset Dementia and Alzheimer's Rates Grow for Younger Americans," part of the Blue Cross Blue Shield,...
At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer's Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the Alzheimer's Drug Discovery Foundation (ADDF). GAP and ADDF reiterates that the health, well-being and safety...
For the first time in 15 years, there are new Alzheimer’s drug treatments on the horizon that are expected to seek regulatory approval by the FDA and leading experts are increasely optimistic that a major breakthrough in Alzheimer’s research will occur within the next five years. We are at a moment of peak opportunity – and there is a pressing need – to connect innovators, funders, and investors to continue...
The Global Alzheimer's Platform Foundation recognizes the impact that GAP-Net site Georgetown University Medical Center's Memory Disorders Program has had on Alzheimer's disease research. We congratulate them on their 20 years of dedication and service to the field. WASHINGTON (WJLA) — It's estimated that one in 10 people 65 and over has Alzheimer's disease. That's nearly 6 million Americans. There is promising research on the horizon, though, thanks in part to...
The Global Alzheimer's Platform Foundation is proud and honored to work with GAP Net site Butler Hospital Memory and Aging Program's Dr. Stephen Salloway, who was named Rhode Island's Man of the Year for 2019. It is the cruelest of diseases. It is the sixth leading cause of death in America. In the United States, an estimated 5.8 million Americans have been diagnosed with Alzheimer’s disease. Statisticians predict that in the next...
It’s fitting that November is National Alzheimer’s Disease Awareness Month and National Family Caregivers Month. Nearly half of all caregivers for older adults in the United States - family, friends and other unpaid caregivers – are caring for someone with Alzheimer’s disease (AD). Caregivers are essential to those living with Alzheimer’s and contribute 18.5 billion hours of care valued at nearly $234 billion. Caregivers for people with Alzheimer’s dementia...
The facts are staggering… every 65 seconds someone in the United States develops Alzheimer’s disease. It is the most expensive disease in America, with the total direct cost of treatment approaching $300 billion annually - greater than for cancer or heart disease. It is the only leading cause of death in the US that cannot be prevented, cured or even slowed. Yet funding to fuel the research and trials needed...
Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) – Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight against Alzheimer’s disease. Alzheimer’s is a national public health crisis, with more than 5.8 million...
First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer's Summit in Washington, D.C.*** Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today by Biogen and Eisai that a new analysis of a larger dataset from clinical studies...
The fight against a global epidemic September is a key month in the fight against Alzheimer’s and other dementias. Driven by Alzheimer’s Disease International, September has been designated as World Alzheimer's Month with World Alzheimer's Day on September 21 to prompt organizations worldwide to raise awareness and challenge the stigma that surround dementia. Global efforts are vital as people of varying races and ethnicities have different levels of risk. These worldwide...
Al Sharpton delivered the keynote address for the Black Health Care Coalition, speaking out against the health care of black people and specifically Alzheimer’s. Turning his attention to the upcoming 2020 election, Sharpton says “All of the candidates running for President of the United States have health plans and should be focusing to eliminate the disparity that causes minorities to face more challenges. There is more we can do in...
George Vradenburg is the head of UsAgainstAlzheimer's, which works to bring the disease to the forefront of government leadership to fund prevention and an eventual cure. CLEVELAND, Ohio -- Alzheimer’s disease afflicts nearly 6 million people in the United States, and sadly affects the many more millions of people who love them. Yet the chairman and co-founder of UsAgainstAlzheimer’s believes that most people -- especially those who could help make...
Spartan will donate $5 to the GAP Transportation Program from each sale of its rapid APOE test to GAP-Net Research Sites Ottawa, Canada (July 31, 2019) – Spartan Bioscience today announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from each sale of its rapid Apolipoprotein E (APOE) genetic pre-screening test to the GAP Transportation...
CLEVELAND, Ohio -- The long quest to find a cure for Alzheimer’s disease could become discouraging. But ordinary people won’t allow that. They are a source of encouragement for doctors and researchers dedicated to stifling the disease, and for the people stricken by it. “Participating in a clinical trial gives me and others the opportunity to do for those who are after us what others did for us in past...
Two RSF Research and Innovation Center patients have been honored as nominees for the Citizen Scientist Award celebrating Alzheimer’s disease clinical trial participants. Wayne Vereen and Sharon Fratepietro have been clinical trial volunteer patients at the RSF Research and Innovation Center for more than four years, and during that time, they’ve received monthly infusions on site. Researchers rely on volunteers to help find a cure. Dr. Jacobo Mintzer and his research...
With support from the nonprofit Global Alzheimer's Platform Foundation, Advocate Lutheran General Hospital and Advocate Research Institute recently honored patients with Alzheimer's disease and their care partners who have participated in Alzheimer's disease research at the Advocate Memory Center. This local ceremony is part of the inaugural Citizen Scientist Awards® Program, the first national awards program honoring Alzheimer's disease clinical trial participants. More than 5.7 million Americans suffer from Alzheimer's...
GAP-Net site Okanagan Clinical Trials in Kelowna, BC recognized three of its Citizen Scientist Awards nominees in a ceremony at the Okanagan Innovation Centre in downtown Kelowna. A dozen times over two years, Gary Millward and his wife, Debra, drove from Quesnel to Kelowna through everything from wildfires and winter storms to rain and brilliant sunshine. The couple was in search of a drug that would slow the brain degeneration...
During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers who are participating in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation (GAP) is recognizing more than 100...
A podcast discussing Alzheimer’s disease – research, risk prevention, and other related topics. Robert Herriman is joined by Phil Sabel, M.A., the Clinical Research Coordinator at GAP-Net site Axiom Clinical Research in Tampa. Click here to listen to the June 13, 2019 episode.
By the time I was old enough to ask my grandmother questions about her life, it was too late. All I had were skeletons of stories I heard from my mom. I knew that it had been difficult for my grandmother when her parents, Irish immigrants on the vaudeville circuit, left her behind to help care for her younger brother when they traveled. But who cared for her? I heard...
The threat of Alzheimer’s disease looms over an aging America, but could a cure be in the offing? And if so, how soon? Experts say the answer is “yes” — and by the year 2025. That’s the date they’re shooting for, anyway. Much as President Kennedy once vowed to send a man to the moon by the year 1970, the federal government now is putting billions of dollars behind a...
NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go unturned in the search for a cure. The Global Alzheimer’s Platform Foundation commends the National...
AzBusiness recognized Dr. Anna Burke as its 2019 Healthcare Innovator of the Year for her work in treating the behavioral and psychiatric disturbances that result from Alzheimer’s disease as well as her work building a community outreach program in the Phoenix area to teach people about brain health, Alzheimer’s, and clinical research. Dr. Burke is a geriatric psychiatrist and director of neuropsychiatry at GAP-Net site Barrow Neurological Institute in Phoenix....
The majority of experts agree that because Alzheimer’s disease is significantly underdiagnosed and underreported, a large number of people may not know they have it. We have both spoken at length about the importance of early detection and diagnosis to allow for earlier interventions and care planning along with a broad array of methods and pathways: pharmacological research and development, increased clinical trials, participation in longitudinal studies, proactive brain health...
Washington, DC (April 10, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability to maintain their memory fitness by expanding supplemental benefits programs that will support memory fitness...
The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. In March 2019, we learned that Biogen and Eisai also terminated late-phase studies. Fortune magazine notes few spaces in the life sciences have fathered failure to the extent that experimental Alzheimer’s drugs have. The Global...
Outside the daffodils and forsythia were blooming, but the group assembled in Nashville, Tennessee, hardly took notice. At the GAP-Net Site Optimization Conference, held February 27–March 1, representatives of 61 academic and private clinical trial sites had eyes and minds trained on efforts aiming to improve how Alzheimer’s disease clinical trials are done—and after years of prep work, some of those efforts are starting to blossom. The changes come as...
The Global Alzheimer's Platform (GAP) Foundation, an organization dedicated to improving Alzheimer's clinical trials in the quest of a cure, has just wrapped the GAP-NET Site Optimization Conference in Nashville. The Feb. 27-March 1 meeting brought together approximately 150 representatives from its network of Alzheimer's clinical research sites. The third annual GAP-NET conference attracted the range of professionals required to successfully plan and launch Alzheimer's clinical trials including major researchers,...
Clinical trials represent future hope for patients seeking better care, and there is no disease more in need of better care than Alzheimer’s disease. While death rates among most cancers, as well as heart disease, HIV-related illness, and other categories, have declined in the past decade, there has been no progress for Alzheimer’s disease. Better health and wellness overall may be having a beneficial effect that has produced a reduction...
GAP President Calls Memory Fitness Programs Through Medicare Advantage “a Game-Changer” Nashville (February 28, 2019)? – Global Alzheimer’s Platform Foundation (GAP) President John Dwyer today announced a roadmap for increasing participation in Alzheimer’s clinical trials by supporting and collaborating with memory fitness supplemental benefit programs offered through select Medicare Advantage plans across the United States. Dwyer made the announcement in a speech to more than 150 experts on Alzheimer’s clinical trials...
Researchers, recruiters, and CEOs from more than 70 Alzheimer’s clinical trial sites to share strategies on finding a cure for the deadly disease From February 27 – March 1, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving Alzheimer’s clinical trials in pursuit of a cure, will convene more than 150 representatives from its network (GAP?Net) of 70+ Alzheimer’s clinical research sites at the Nashville Marriott at Vanderbilt...
There are many open, important clinical trials in Tennessee right now targeting Alzheimer’s disease and related conditions. It’s been 18 months since Nashville legend Glen Campbell died after a long battle with Alzheimer’s disease. Glen and his family bravely shared his heartbreaking journey in the hope of inspiring better care and research for the disease, for which there is no known cure. Glen even sang about it: “I'm never gonna...
Global Alzheimer’s Platform Foundation recognizes strong, expanding research WASHINGTON, DC (February 19, 2019) - The Global Alzheimer's Platform Foundation (GAP) announced a $100,000 grant to the Barrow Neurological Foundation to optimize and support the Alzheimer’s clinical trials program at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center. The grant will go toward participant retention efforts, staff education programs, improving productivity and building a database for clinical trial recruitment. “Barrow Neurological Institute is...
Grant Funds January 28 Community Event at Ontario Science Centre and Expanded Clinical Trial Education Programs TORONTO – January 22, 2019 ---The Global Alzheimer’s Platform Foundation and Toronto Memory Program have initiated a multi-faceted project to educate the Ontario community about Alzheimer’s disease, brain health and the role of Alzheimer’s clinical trials. Toronto Memory Program is a member of the GAP-Net network of 70 prominent research sites working with the nonprofit Global Alzheimer’s Platform Foundation to speed and improve...
Event is on November 8, Chicago Alzheimer’s Awareness Day On November 8th - Chicago Alzheimer's Awareness Day - Great Lakes Clinical Trials and the Global Alzheimer's Platform Foundation are hosting a major community event for people in the community who are interested in learning more about memory concerns and Alzheimer's disease. Research volunteers, including care partners, are being honored and celebrated, and will share their personal stories and motivation for volunteering. People from the community will...
WASHINGTON, D.C. – “I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its network of leading academic and private research centers; forging partnerships with healthcare professionals to increase...
Winners to be recognized at UsAgainstAlzheimer’s 2019 National Summit in Washington, D.C. WASHINGTON, D.C. (September 25, 2018) – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical trial participants. The awards are designed to broaden awareness of the benefits of clinical research for...
Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures.A new report from top researchers says the number of drugs advancing through clinical phase two and phase three trials provides reason to believe that breakthroughs may be in the current pharmaceutical pipeline.The...
Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new partnership will help the patient experience and increase efficiency and lower costs. Raleigh Neurology is one of 15...
Lyft drivers will transport clinical trial participants to and from GAP-Net research sites WASHINGTON, D.C. (Mar. 20, 2018) – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who are part of Eli Lilly and Company’s (Lilly) study TRAILBLAZER-ALZ, an Alzheimer’s disease clinical trial testing...
WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial system by collaborating with our 59 (and growing) GAP-Net research sites to reduce time-to-trial by...
Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than 30 percent of total trial time is spent simply recruiting patients. Those issues are present...
Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life. My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be seen until after all of the white patients were assisted. It was at that moment...
More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. It is projected that 14 million people in the U.S. will be afflicted with Alzheimer’s...
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), a Washington- based entity launched in 2015 by UsAgainstAlzheimer’s and the Global CEO Initiative (CEOi) on...
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost Bipartisan Support is Good Newsfor 5.5 Million Americans Living with Alzheimer’s and their Caregivers WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National Institutes of Health (NIH) will receive a $2 billion boost in fiscal year 2017, as...
Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise physiologist coaches her to push harder. “Can you hang in there like for 15 more...
Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer's Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based on her vast experience working as a healthcare executive with leading healthcare companies. The three-year...
A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the ground. To address this, the Global Alzheimer’s Platform Foundation commissioned a survey to examine Americans’...
First?of?its?Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. (July 28, 2016) – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP?Net, a first?of?its?kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP?Net currently has 11 leading academic and private commercial research site partners. The network looks to add a minimum of 20 more sites by...
Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role WASHINGTON, D.C. (July 27, 2016) – Global Alzheimer's Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this role, Dr. Zhong will lead strategic development advancing GAP’s efforts to disrupt the inefficient clinical...
Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier?to?use clinical trial participation tools, including the Brain Health Registry WASHINGTON, D.C. (July 18, 2016) – In a first?ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating in Alzheimer’s disease clinical trials, but participation rates show that less than 10% are actually...